Silence Therapeutics PLC Sponsored ADR (SLN) shares surged 7.2% on the latest trading session, closing at $10.45, with significantly higher trading volume than usual. The company’s stock has risen 45.3% over the past month, driven by growing optimism around its RNA interference pipeline and anticipated clinical data, particularly from the ongoing Phase II SANRECO study on divesiran, which will report topline results in August 2026.
The upcoming quarterly earnings report is expected to reveal a loss of $0.32 per share, a year-over-year change of +40.7%, while revenues are projected at $3.14 million, marking a 1325% increase from the previous year. Silence Therapeutics is also in talks for a strategic partnership to advance its late-stage siRNA candidate for cardiovascular disease and is regaining global rights to SLN312 from AstraZeneca, allowing further evaluation of its development options.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
